Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2021 from OUS - Metastasis - molecular studies and development of methods

21 publications found

Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G (2021)
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
Front Immunol, 12, 663865
DOI 10.3389/fimmu.2021.663865, PubMed 34046035

Cangiano M, Grudniewska M, Salji MJ, Nykter M, Jenster G, Urbanucci A, Granchi Z, Janssen B, Hamilton G, Leung HY, Beumer IJ (2021)
Gene Regulation Network Analysis on Human Prostate Orthografts Highlights a Potential Role for the JMJD6 Regulon in Clinical Prostate Cancer
Cancers (Basel), 13 (9)
DOI 10.3390/cancers13092094, PubMed 33925994

Christensen SB, Simonsen HT, Engedal N, Nissen P, Møller JV, Denmeade SR, Isaacs JT (2021)
From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug Development
Prog Chem Org Nat Prod, 115, 59-114
DOI 10.1007/978-3-030-64853-4_2, PubMed 33797641

Dominguez-Valentin M, Plazzer JP, Sampson JR, Engel C, Aretz S, Jenkins MA, Sunde L, Bernstein I, Capella G, Balaguer F, Macrae F, Winship IM, Thomas H, Evans DG, Burn J, Greenblatt M, de Vos Tot Nederveen Cappel WH, Sijmons RH, Nielsen M, Bertario L, Bonanni B, Tibiletti MG, Cavestro GM, Lindblom A, Valle AD et al. (2021)
No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study
J Clin Med, 10 (13)
DOI 10.3390/jcm10132856, PubMed 34203177

Ellingsen EB, Mangsbo SM, Hovig E, Gaudernack G (2021)
Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential
Front Immunol, 12, 682492
DOI 10.3389/fimmu.2021.682492, PubMed 34290704

Gundersen S, Boddu S, Capella-Gutierrez S, Drabløs F, Fernández JM, Kompova R, Taylor K, Titov D, Zerbino D, Hovig E (2021)
Recommendations for the FAIRification of genomic track metadata
F1000Res, 10
DOI 10.12688/f1000research.28449.1, PubMed 34249331

Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å (2021)
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
J Transl Med, 19 (1), 232
DOI 10.1186/s12967-021-02905-3, PubMed 34059094

Kim SJ, Lubinski J, Huzarski T, Møller P, Armel S, Karlan BY, Senter L, Eisen A, Foulkes WD, Singer CF, Tung N, Bordeleau L, Neuhausen SL, Olopade OI, Eng C, Weitzel JN, Fruscio R, Narod SA, Kotsopoulos J, Hereditary Ovarian Cancer Clinical Study Group (2021)
Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers
Cancer Epidemiol Biomarkers Prev (in press)
DOI 10.1158/1055-9965.EPI-21-0296, PubMed 34426412

Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A, Adamopoulos IE, Adeli K, Adolph TE, Adornetto A, Aflaki E, Agam G, Agarwal A, Aggarwal BB, Agnello M, Agostinis P, Agrewala JN, Agrotis A, Aguilar PV, Ahmad ST, Ahmed ZM et al. (2021)
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, 17 (1), 1-382
DOI 10.1080/15548627.2020.1797280, PubMed 33634751

Kukkonen K, Taavitsainen S, Huhtala L, Uusi-Makela J, Granberg KJ, Nykter M, Urbanucci A (2021)
Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response
Cancers (Basel), 13 (13)
DOI 10.3390/cancers13133325, PubMed 34283056

Kværner AS, Birkeland E, Bucher-Johannessen C, Vinberg E, Nordby JI, Kangas H, Bemanian V, Ellonen P, Botteri E, Natvig E, Rognes T, Hovig E, Lyle R, Ambur OH, de Vos WM, Bultman S, Hjartåker A, Landberg R, Song M, Blix HS, Ursin G, Randel KR, de Lange T, Hoff G, Holme Ø et al. (2021)
The CRCbiome study: a large prospective cohort study examining the role of lifestyle and the gut microbiome in colorectal cancer screening participants
BMC Cancer, 21 (1), 930
DOI 10.1186/s12885-021-08640-8, PubMed 34407780

Lesueur F, Easton DF, Renault AL, Tavtigian SV, Bernstein JL, Kote-Jarai Z, Eeles RA, Plaseska-Karanfia D, Feliubadaló L, Spanish ATM working group, Arun B, Herold N, Versmold B, Schmutzler RK, GC-HBOC, Nguyen-Dumont T, Southey MC, Dorling L, Dunning AM, Ghiorzo P, Dalmasso BS, Cavaciuti E, Le Gal D, Roberts NJ, Dominguez-Valentin M et al. (2021)
First international workshop of the ATM and cancer risk group (4-5 December 2019)
Fam Cancer
DOI 10.1007/s10689-021-00248-y, PubMed 34125377

Mattingsdal M, Ebenesersdóttir SS, Moore KHS, Andreassen OA, Hansen TF, Werge T, Kockum I, Olsson T, Alfredsson L, Helgason A, Stefánsson K, Hovig E (2021)
The genetic structure of Norway
Eur J Hum Genet
DOI 10.1038/s41431-021-00899-6, PubMed 34002043

Nakken S, Lilleby W, Switlyk MD, Knudsen KE, Lilleby O, Zhao S, Kaveh F, Ekstrøm PO, Urbanucci A, Hovig E (2021)
The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology
J Pers Med, 11 (5)
DOI 10.3390/jpm11050330, PubMed 33922147

Nakken S, Saveliev V, Hofmann O, Møller P, Myklebost O, Hovig E (2021)
Cancer Predisposition Sequencing Reporter (CPSR): A flexible variant report engine for high-throughput germline screening in cancer
Int J Cancer, 149 (11), 1955-1960
DOI 10.1002/ijc.33749, PubMed 34310709

Schläfli AM, Tokarchuk I, Parejo S, Jutzi S, Berezowska S, Engedal N, Tschan MP (2021)
ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells
Sci Rep, 11 (1), 9011
DOI 10.1038/s41598-021-87966-6, PubMed 33907223

Seppälä TT, Dominguez-Valentin M, Crosbie EJ, Engel C, Aretz S, Macrae F, Winship I, Capella G, Thomas H, Hovig E, Nielsen M, Sijmons RH, Bertario L, Bonanni B, Tibiletti MG, Cavestro GM, Mints M, Gluck N, Katz L, Heinimann K, Vaccaro CA, Green K, Lalloo F, Hill J, Schmiegel W et al. (2021)
Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report
Eur J Cancer, 148, 124-133
DOI 10.1016/j.ejca.2021.02.022, PubMed 33743481

Seppälä TT, Latchford A, Negoi I, Sampaio Soares A, Jimenez-Rodriguez R, Sánchez-Guillén L, Evans DG, Ryan N, Crosbie EJ, Dominguez-Valentin M, Burn J, Kloor M, Knebel Doeberitz MV, Duijnhoven FJBV, Quirke P, Sampson JR, Møller P, Möslein G, European Hereditary Tumour Group (EHTG) and European Society of Coloproctology (ESCP) (2021)
European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender
Br J Surg, 108 (5), 484-498
DOI 10.1002/bjs.11902, PubMed 34043773

Solis N, Zavaleta E, Wernhoff P, Dominguez-Barrera C, Dominguez-Valentin M (2021)
Challenges to Bringing Personalized Medicine to a Low-Resource Setting in Peru
Int J Environ Res Public Health, 18 (4)
DOI 10.3390/ijerph18041470, PubMed 33557277

Stjepanovic N, Lubinski J, Moller P, Randall Armel S, Foulkes WD, Tung N, Neuhausen SL, Kotsopoulos J, Sun P, Sun S, Eisen A, Narod SA, Hereditary Breast Cancer Clinical Study Group (2021)
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers
Breast Cancer Res Treat, 187 (2), 515-523
DOI 10.1007/s10549-020-06072-9, PubMed 33423179

Taavitsainen S, Engedal N, Cao S, Handle F, Erickson A, Prekovic S, Wetterskog D, Tolonen T, Vuorinen EM, Kiviaho A, Nätkin R, Häkkinen T, Devlies W, Henttinen S, Kaarijärvi R, Lahnalampi M, Kaljunen H, Nowakowska K, Syvälä H, Bläuer M, Cremaschi P, Claessens F, Visakorpi T, Tammela TLJ, Murtola T et al. (2021)
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
Nat Commun, 12 (1), 5307
DOI 10.1038/s41467-021-25624-1, PubMed 34489465

 
Page visits: 652917